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Abstract
As detection rates of non-albicans Candida species are increasing, determining their pathogen profiles and antifungal susceptibilities
is important for antifungal treatment selection. We identified the antifungal susceptibility patterns and predictive factors for mortality in
candidemia.
A multicenter retrospective analysis of patients with at least 1 blood culture positive for Candida species was conducted. Candida
species were classified into 3 groups (group A, Candia albicans; group B, Candida tropicalis, and Candida parasilosis; group C,
Candida glabrata and Candida krusei ) to analyze the susceptibility patterns, first-line antifungal administered, and mortality.
Univariate and multivariate comparisons between outcomes were performed to identify mortality risk factors.
In total, 317 patients were identified, and 136 (42.9%) had recorded mortality. Echinocandin susceptibility was higher for group A
than group B (111/111 [100%] vs 77/94 [81.9%], P< .001). Moreover, group A demonstrated higher fluconazole susceptibility
(144/149 [96.6%] vs 39/55 [70.9%], P< .001) and lower mortality (68 [45.3%] vs 34 [61.8%], P= .036) than those of group C. In the
multivariate analysis, the sequential organ failure assessment score (odds ratio OR 1.351, 95% confidence interval 1.067–1.711,
p=0.013) and positive blood culture on day 7 of hospitalization (odds ratio 5.506, 95% confidence interval, 1.697–17.860, P= .004)
were associated with a higher risk of mortality.
Patientswith higher sequential organ failure assessment scores and sustainedpositive bloodcultures have an increased risk ofmortality.
Abbreviations: C albicans = Candida albicans, C glabrata = Candida glabrata, C krusei = Candida krusei, C parapsilosis =
Candida parasilosis, C tropicalis = Candida tropicalis, CI = confidence interval, CLSI = Clinical and Laboratory Standards Institute,
CVC = central venous catheters, EUR = Europe, ICU = intensive care unit, MICs = minimal inhibitory concentrations, NA = North
America, OR = odds ratio, SOFA = sequential organ failure assessment.
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[2]1. Introduction
Candida species are normal flora of the gastrointestinal and
genitourinary tracts. However, in hosts with a decreased immune
response, widespread dissemination can result in multi-organ
failure.[1] The term candidemia refers to the presence of CandidaEditor: Leyi Wang.
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species in the blood. Candida species identified from blood
should never be considered contaminants, because that is the
most common manifestation of invasive candidiasis.[2] Risk
factors for candidemia include patients who have been treated in
an intensive care unit (ICU) and those who are immunocompro-nd its supplementary/additional information files. However raw dataset are
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Jung et al. Medicine (2020) 99:11 Medicinemised.[3] Identified risk factors for developing candidemia are
patients in the ICU with indwelling central venous catheters
(CVC), those receiving total parental nutrition, and those who
have undergone gastrointestinal procedures.[4]
Although infection with Candida albicans (C albicans) is most
common, the identification of the casual species is important,
because some species are more resistant to azole antifungal
agents.[2] The isolation of non-albicans Candida species has been
increasing, and they have been frequently identified in the
following order: Candida glabrata (C glabrata) and Candida
parapsilosis, followed by Candida tropicalis (C tropicalis) and
Candida krusei (C krusei).[5,6] Some C glabrata isolates are
resistant to fluconazole, and allC krusei isolates are considered to
be intrinsically resistant to fluconazole.[7] The minimal inhibitory
concentrations (MICs) for echinocandins for Candida parasilosis
(C parapsilosis) are higher than those of other Candida species.
Moreover, resistance to fluconazole is highly predictive of
resistance to voriconazole.[7] Therefore, the identification of
changes in pathogen profiles and antifungal susceptibilities is
important for antifungal treatment selection. Our study specifi-
cally compared the clinical, epidemiological, and antifungal
susceptibility patterns in candidemia and identified risk factors
for mortality.2. Materials and methods
2.1. Study population and definitions
A multicenter retrospective analysis of episodes of candidemia in
adults, collected from the electronic databases of 2 tertiary care
hospitals in South Korea, was performed over a 4-year (2012–
2015) period. Patients with at least 1 positive blood culture for a
Candida species were included in the analysis. Patients with
isolated yeasts other than Candida species were excluded from
the study.
Intravenous catheter-related candidemia was defined in
patients who had an intravascular device and ≥1 positive blood
culture result, such that the same organism was isolated from the
catheter and a peripheral blood culture, with clinical manifes-
tations of infection (fever, chills, and/or hypotension) and no
other apparent source for the bloodstream infection.[8] An intra-
abdominal source of candidemia was considered for the patients
who had a recent abdominal surgery or intra-abdominal events,
such as peritonitis, abdominal abscess, and a purulent or necrotic
infection at sites of gastrointestinal perforation or anastomotic
leak, as confirmed by computed tomography scans.[1] Cardio-
vascular disease in patients was defined as the presence of
hypertension, valvular heart disease, ischemic heart disease, or
heart failure. Central nervous system disorder in patients was
defined by a history of cerebrovascular accident or hemorrhage.
Renal disease in patients was defined by chronic renal failure,
stage 3 or 4, requiring hemodialysis or peritoneal dialysis. Lung
disease in patients was defined as the presence of asthma, chronic
obstructive lung disease, or idiopathic pulmonary fibrosis.
Hematologic disease in patients was defined by aplastic anemia,
lymphoma, or leukemia. The use of echinocandin was defined in
patients who received first-line antifungal treatment with
caspofungin, anidulafungin, or micafungin.
The demographic data, comorbidities, hospitalization and ICU
stay, laboratory results, treatment outcomes, Candida species
distribution, antifungal susceptibility results, first-line antifungal
agents administered, and the complications (endocarditis, bone2
or joint infection, hepatosplenic candidiasis, and endophthalmi-
tis) related to the candidemia were compared among the
outcomes. The severity of illness was estimated by the sequential
organ failure assessment (SOFA) score and the Charlson index.
The laboratory data obtained on the first day of admission were
analyzed. The presence of CVC insertion at the time of the
positive blood culture and whether the patient was admitted to
the ICU or the general ward were compared between outcomes.
Blood culture results positive for a Candida species, obtained on
the 7th, 14th, and 28th hospital day, were analyzed. The
appropriate antifungal treatment was considered when the
treatment was started within 48hours, after the first blood
culture was performed.[9] Univariate and multivariate compar-
isons between outcomes were performed.
Candida species were classified as C albicans (group A) and
non-albicans Candida species groups (groups B and C). Among
the non-albicans group, species with reduced susceptibility to
fluconazole were classified as group C (C glabrata and C krusei),
and species susceptible to fluconazole classified as group B (C
tropicalis and C parapsilosis). The clinical and demographic
factors, susceptibility patterns, first-line antifungal treatment,
and mortality of each groups were analyzed.2.2. Laboratory testing
Using the BACTEC 860 system (Becton Dickinson, Inc., Sparks,
MD), isolated Candida were detected from blood cultures.
Candida species were identified using the API-32C system
(BioMerieux Vitek, Inc., St. Louis, MI). The commercial VITEK-
2 yeast susceptibility test (BioMerieux, Hazelwood, MO) was
used to derive the MICs for Candida species. Susceptibility to
echinocandin and fluconazole was defined as follows according
to the clinical breakpoints for interpreting the MICs from the
Clinical and Laboratory Standards Institute (CLSI) guidelines.
Susceptibility to echinocandins was defined in isolates of C
albicans, C tropicalis, and C krusei with an MIC 0.25mcg/mL,
and C parasilosis with an MIC 2mcg/mL for all 3
echinocandins (anidulafungin, caspofungin, and micafungin).
C glabrata isolates with an MIC 0.12mcg/mL to caspofungin
and anidulafungin, and an MIC 0.06mcg/mL to micafungin
were considered susceptible.[10] The CLSI does not currently
provide a susceptible breakpoint of fluconazole for C glabrata,
with the intermediate breakpoint defined as MIC 32 and
resistance as MIC ≥64. Susceptible was an MIC 2mcg/mL for
fluconazole in all species of Candida, except for C glabrata andC
krusei (Supplementary Table 1, http://links.lww.com/MD/
D953).[11]
The authors confirm that the ethical policies of the journal, as
noted on the journal’s author guidelines page, have been adhered
to and the appropriate ethical review committee approval has
been received.2.3. Statistical analysis
Categorical variables have been presented as numbers and
percentages, and continuous variables have been expressed as the
mean± standard deviation, unless otherwise indicated. Categori-
cal variables were compared using a x2 analysis, and continuous
variables with normal distributions were compared using the
Student t test. Single linear univariate correlations (Pearson
correlation coefficients) and stepwise multivariate regression
analyses were performed to evaluate the relationship between
Jung et al. Medicine (2020) 99:11 www.md-journal.commortality and other variables. The covariates inserted in this
model included the variables that differed with a P< .05 in the
univariate analysis, which ensured the absence of significant
multicollinearity. Multiple differences among groups of
C albicans and non-albicans species were evaluated using a
1-way Analysis of Variance (ANOVA) with Tukey multiple
comparison test. All categories were calculated as a percentage
with a 95% confidence interval (CI). All statistical tests were
performed using IBM SPSS software for Windows, version 20. P-
values< .05 were considered statistically significant.3. Results
During the study period, a total of 317 patients (88 cases
originating from indwelling intravenous catheter, 89 cases from
an intra-abdominal source, and 140 cases with an unidentifiable
source of candidemia) were analyzed. Among these patients,
mortality was observed for 136 (42.9%) patients.
The baseline characteristics and demographic data of the study
population are presented in Table 1. Among the study patients,Table 1
Baseline characteristics of the study population.
Characteristic Total (n=317)








Cardiovascular disease 179 (56.5)
CNS disorder 91 (28.7)
Solid organ cancer 109 (34.5)
Renal disease 96 (30.3)
Liver disease 59 (18.6)
Lung disease 164 (51.7)
Solid organ transplantation 8 (2.5)
Hematologic disease 110 (34.7)
Risk factor for infection
CVC 149 (47.0)











Culture positive on day 7 42 (48.8)
Culture positive on day 14 10 (18.5)
Culture positive on day 28 2 (6.5)
Complication related to candidemia 9 (2.8)
The data were expressed as the mean±SD or median (interquartile range) or number of patients (%).
ALT= alanine aminotransferase, AST=aspartate aminotransferase, BMI=body mass index, BUN=blood u
intensive care unit, SOFA= sequential organ failure assessment, WBC=white blood cell.
∗
Pearson x-test.
† Student t test.
‡ Fisher exact test.
3
198 (62.5%) were male with a median age of 68.3±13.5 years.
Patients with renal failure (36 [19.9%] vs 60 [44.1%], P< .001),
chronic lung diseases (71 [39.2%] vs 93 [68.4%], P< .001), and
hematologic disorders (48 [26.5%] vs 62 [45.6%], P< .001)
presented with higher rates of mortality. Moreover, higher
mortality was observed in the patients with higher SOFA scores
(2.9±2.9 vs 6.2±4.3, P< .001), higher Charlson index (3.1±1.8
vs 3.8±1.9, P= .003), a CVC in place at the time of candidemia
(74 [40.9%] vs 75 [55.1%], P= .012), and those admitted to the
ICU (49 [27.1%] vs 67 [49.3%], P< .001). Patients with positive
culture results on the 7th day of hospitalization demonstrated
higher mortality rates than those with negative culture results
(21 [35.6%] vs 21 [77.8%], P< .001).
Table 2 presents the predictive factors associated with an
increased risk of mortality. Higher SOFA scores (odds ratio [OR]
1.351, 95% CI 1.067–1.711, P= .013) and positive culture
results on the 7th day of hospitalization (OR 5.506, 95% CI,
1.697–17.860, P= .004) were associated with an increased risk of
mortality. The multivariate analysis demonstrated that there was
no statistically significant difference in mortality based on theSurvival (n=181) Mortality (n=136) P-value








100 (55.2) 79 (58.1) .614
∗
51 (25.2) 40 (29.4) .810
∗
66 (36.5) 43 (31.9) .394
∗
36 (19.9) 60 (44.1) <.001
∗
33 (18.2) 26 (19.1) .841
∗
71 (39.2) 93 (68.4) <.001
∗
6 (3.3) 2 (1.5) .474‡
48 (26.5) 62 (45.6) <.001
∗
74 (40.9) 75 (55.1) .012
∗










21 (35.6) 21 (77.8) <.001
∗
7 (17.1) 3 (23.1) .689‡
1 (4.3) 1 (12.5) .456‡
7 (3.9) 2 (1.5) .309‡
rea nitrogen, CNS= central nervous system, CVC=central venous catheter, Hb=haemoglobin, ICU=
Table 2
Predictive factors for mortality.
Univariate analysis Multivariate analysis
Variables OR 95% CI P-value OR 95% CI P-value
Hematologic disease 2.322 1.448–3.722 <.001 0.861 0.218–3.399 .830
Presence of CVC 1.778 1.134–2.787 .012 0.767 0.206–2.852 .767
ICU admission 2.616 1.636–4.184 <.001 1.371 0.303–6.200 .682
Hospital, days 0.995 0.990–1.000 .037 0.997 0.986–1.009 .655
SOFA score 1.294 1.199–1.396 <.001 1.351 1.067–1.711 .013
Charlson index 1.201 1.063–1.357 .003
Culture positive on day 7 6.333 2.211–18.139 .001 5.506 1.697–17.860 .004
Candida species
Candida albicans 1
Candida tropicalis, Candida parasilosis 0.612 0.363–1.033 .066
Candida glabrata, Candida krusei 1.665 0.872–3.181 .122
Treatment
No antifungal 1
Fluconazole 0.636 0.383–1.055 .080
Echinocandin 0.148 0.041–0.541 .004
CI= confidence interval, CVC= central venous catheter, ICU= intensive care unit, Logistic regression analysis, OR= odds ratio, SOFA= sequential organ failure assessment.
Jung et al. Medicine (2020) 99:11 MedicineCandida species. Although the univariate analysis showed that
echinocandin use resulted in a lower risk of mortality compared
to no antifungal treatment (OR 0.148, 95% CI 0.041–0.541,
P= .004), there was no statistically significant difference in the
multivariate analysis.
Table 3 presents the characteristics of the C albicans (group A)
and non-albicans Candida species groups (groups B and C).
The isolates were identified as C albicans, C parapsilosis or C
tropicalis, and C glabrata or C krusei in 150, 112, and 55 cases
(C albicans [n=150], C parasilosis [n=60], C tropicalis [n=52],
C glabrata [n=47], and C krusei [n=8]), respectively. No other
Candida species were isolated. NomultipleCandida isolates were
identified from the same patient, and no mixed infections were
identified. Susceptibility to echinocandin was higher for group A
than group B (111/111 [100%] vs 77/94 [81.9%], P< .001).
Group A presented higher susceptibility to fluconazole than
that of group C (144/149 [96.6%] vs 39/55 [70.9%], P< .001).
There was no difference in mortality between groups A and B.
However, lower mortality was observed for group A than group
C (68 [45.3%] vs 34 [61.8%], P= .036).
Figure 1 presents the percentages for echinocandin and
fluconazole susceptibility for each group of Candida species.
4. Discussion
Candidemia is 1 of the most common causes of health-care
associated blood stream infections.[1] Among 1,314 Candida
isolates tested from the Asia-Pacific region, C albicans (46.0%)
was the most commonly isolated species followed by C glabrata
(17.9%), C tropicalis (14.1%), C parapsilosis (12.9%), and C
krusei (1.8%).[12] Although C albicans is the most commonly
isolated species, an increase in non-albicans Candida species has
been observed worldwide.[1]C glabrata was the most common
non-C albicans species detected in all geographic regions except
for Latin America, where C parapsilosis and C tropicalis were
more common.[12] Both Europe (EUR) and North America (NA)
demonstrated similar species distribution with C albicans (EUR
52.5%,NA 42.7%) the most commonly isolated species followed
by C glabrata (EUR 16.0%, NA 24.3%).[12] In South Korea,4
although C albicans remains the leading Candida species that
causes blood stream infection, an increase of C glabrata (from
21.3% to 28.5%) and a decrease of C parapsilosis (from 36.5%
to 24.7%) over the past years were noticed.[13]C auris an
emerging pathogen because it is intrinsically fluconazole
resistant, and increasing numbers of infections have been
identified in multiple countries.[14,15] This pathogen has caused
invasive health care-associated infections, and it has been
associated with high mortality rates.[15] The earliest known
strain ofC auris dates to 1996 in South Korea.[16] In this study,C
albicans (n=150) was the most commonly isolated pathogen,
followed by C parapsilosis (n=60), C tropicalis (n=52), C
glabrata (n=47), and C krusei (n=8).
A reduced dose-dependent susceptibility to fluconazole was
observed for the C glabrata isolates compared to the other
Candida species.[17] The highest rates of fluconazole resistant
isolates were seen in C glabrata from North America (10.6%)
and in C tropicalis from the Asia-Pacific region (9.2%).[12]
Fluconazole resistance for C albicans was low in both North
America (0.4%), and Asia-Pacific regions (0.2%).[12] In this
study, 3.4% of C albicans were resistant to fluconazole, with C
glabrata, and C krusei isolates exhibiting higher resistance to
fluconazole than C. albicans.Due to an altered cytochrome P450
isoenzyme, C krusei is intrinsically resistant to fluconazole.[18] In
a large international surveillance study that included 326
bloodstream isolates of C krusei, all of the isolates were
susceptible to echinocandins.[19] Echinocandin resistance ranged
from 3.5% for C glabrata to 0.1% for C albicans and C
parapsilosis across the globe.[12] In the present study, C tropicalis
andC parapsilosis isolates were less susceptible to echinocandins,
as has been reported in prior studies.[17,20]
Prior studies have identified increasing age, higher Acute
Physiology and Chronic Health Evaluation II scores, the Candida
species, underlying renal dysfunction, and the primary antifungal
agent selected as factors that are associated with an increased risk
of mortality.[21–23] Although a higher SOFA score demonstrated
an association with an increased risk of mortality, which has been
shown in prior studies, there was no statistically significant
difference in mortality among theCandida species or the primary
antifungal agent administered.
Table 3










C (n=55) P-value P-value
∗
P-value†
Age, yr 74.6±13.2jj 69.2±13.3jj 73.8±14.6 .004 .004 .923
Gender, male 88 (58.7) 76 (67.9) 34 (61.8) .407‡ .128 .684
Hospital, d 48.9±3.7 65.9±87.6 57.4±43.1 1.000 .082 .673
ICU, d 18.8±21.6 21.4±29.2 17.7±19.7 .652 .716 .970
SOFA score 4.4±4.0 4.2±3.9 4.3±3.5 .885 .874 .979
Charlson index 3.4±1.8 3.1±1.7 3.8±2.2 .072 .382 .383
Underlying disease
Cardiovascular disease 88 (58.7) 59 (52.7) 32 (58.2) .721‡ .334 .950
CNS disorder 39 (26.0) 38 (33.9) 14 (25.5) .706‡ .163 .937
Solid organ cancer 50 (33.6) 37 (33.0) 22 (40.0) .484‡ .930 .393
Renal disease 48 (32.0) 28 (25.0) 20 (36.4) .900‡ .217 .557
Liver disease 28 (18.7) 21 (18.8) 10 (18.2) .951‡ .986 .937
Lung disease 89 (59.3) 51 (45.5) 24 (43.6) .017‡ .027 .045
Solid organ transplantation 2 (1.3) 5 (4.5) 1 (1.8) .503‡ .141x 1.000x
Hematologic malignancy 2 (1.3) 6 (5.4) 4 (7.3) .028‡ .077x .046x
Connective tissue disease 9 (6.0) 15 (13.4) 11 (20.0) .003‡ .04 .003
Risk factor for infection
CVC in place at time of positive blood culture 80 (53.3) 48 (42.9) 21 (38.2) .031‡ .093 .055
ICU admission 59 (39.3) 43 (38.4) 14 (25.5) .110‡ .877 .066
Laboratory data
WBC (109/L) 1874±4411 2100±5763 1847±5058 .925 .931 .999
Hb (g/dL) 10.4±2.9 10.3±1.5 10.1±2.1 .611 .883 .589
Platelet (109/L) 35676±81745 49810±123832 32381±89167 .446 .508 .977
AST (U/L) 85.6±192.1 200.8±967.6 54.8±63.1 .287 .336 .954
ALT (U/L) 55.6±116.9 57.7±108.0 39.9±49.2 .631 .990 .678
Total bilirubin 20.7±194 3.05±9.32 1.86±4.93 .568 .616 .701
BUN (mg/dL) 37.0±31.1jj 28.8±24.9jj 35.2±24.4 .059‡ .05 .904
Creatinine (mg/dL) 1.4±1.4 1.8±3.9 1.6±1.7 .570 .544 .880
Microbiological data
Culture positive on day 7 18 (31.0) 13 (28.3) 11 (50.0) .369‡ .183x .285
Culture positive on day 14 2 (6.7) 6 (24.0) 2 (15.4) .768‡ 1.000x .658x
Culture positive on day 28 1 (5.0) 1 (5.0) 0 (0) .368‡ .464x
Susceptibility
Echinocandin S (n=251) 111/111 (100) 77/94 (81.9) 45/46 (97.8) .064‡ <.001 .293x
Fluconazole S (n=316) 144/149 (96.6) 108/112 (96.4) 39/55 (70.9) <.001‡ 1.000x <.001
Treatment
Echinocandin (n=67) 30 (20.0) 22 (19.6) 15 (27.3) .350‡ 1.000 .265
Fluconazole (n=236) 114 (76.0) 88 (78.6) 34 (61.8) .110‡ .624 .045
Complication 4 (2.7) 2 (1.8) 3 (5.5) .443‡ 1.000x .388x
Mortality 68 (45.3) 34 (30.4) 34 (61.8) .305‡ 1.000x .036
The data were expressed as the mean±SD or median (interquartile range) or number (%) of patients.
C albicans=Candida albicans, C glabrata=Candida glabrata, C krusei=Candida krusei, C parapsilosis=Candida parasilosis, C tropicalis=Candida tropicalis, CVC= central venous catheter, ICU= intensive
care unit, R= resistant, S= susceptible, SOFA= sequential organ failure assessment.
∗
P-value between Group A and Group B.
† P-value between Group A and Group C. The P-value was evaluated by 1-way ANOVA among the 3 groups.
‡ Linear-by linear association.
x Fisher exact test.
jj Statistically significant difference between 2 groups based on Tukey post hoc test.
Jung et al. Medicine (2020) 99:11 www.md-journal.comIn this study, positive blood culture results obtained 1week after
hospitalizationwere associatedwith a nearly 5 times greater risk of
mortality. For cases of deep-seated candidemia, blood culture
positivity is estimated to be less than 50%.[24] Considering the low
sensitivity of culture positivity in deep-seated candidemia, we
believe that this finding raises awareness for clinicians, by
indicating that Candida species isolated from blood should never
be considered contaminants, and that patients with a positive
blood culture after 1 week are at higher risk for a poor outcome.5
There are several limitations to this study. First, this study is
limited by its retrospective nature. Second, the clinical MIC
breakpoints for both the echinocandins and fluconazole were
defined according to the CLSI guidelines. Third, describing
geometric means, MIC ranges, MIC 50 and MIC 90 values was
not possible in this study.
The results of our study demonstrate the antifungal suscepti-
bility patterns of Candida species at 2 hospitals in South Korea.
Moreover, patients with higher SOFA scores at the time of
Figure 1. Antifungal susceptibility.
Jung et al. Medicine (2020) 99:11 Medicineadmission and a positive culture on the 7th day of hospitalization
are at an increased risk of mortality.Author contributions
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